Baxter International Inc.

Baxter Healthcare Sa

George Owoo

Richard A Burgos

Kenneth E Burhop

Satish K Pejaver

Deepak Tiwari

Rekha Nayak

Jie Liu

Disclosed are concentrate esmolol injection essentially free from other related esters of esmolol and diluted esmolol compositions. The concentrate esmolol formulation includes from about 25-1000 mg/ml of esmolol and about 1-25% w/v of benzyl alcohol and the combination thereof. The compositions can also be used as multi-dose compositions. The present invention also discloses diluted, ready-to-use compositions of esmolol prepared by dilution of the present invention concentrates. Also disclosed are methods of making and using the ready-to-use compositions of the present invention.

Multi-dose concentrate esmolol with benzyl alcohol

A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation.

Colored esmolol concentrate

An aqueous, stable, sterile pharmaceutical composition of the thrombin inhibitor argatroban in a solution containing an acid to solubilize the argatroban, substantially free from dehydrated alcohol is described, as well as a method for its preparation.

Argatroban formulation

Formulations comprising argatroban and methods of making and using the formulations are provided. In an embodiment, the formulation comprises a solution having an argatroban concentration ranging from greater than about 10 to about 500 mg/mL. The solution can comprise an aqueous solution. The solution can be packaged in a sealed container that may either be aseptically-filled or subjected to sterilization to reduce the microbiological burden of the formulation. The solution can further be diluted and administered to persons needing same.

Argatroban formulations and methods for making and using same

An aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions, comprising methyl-3-&lsqb;4-(2-hydroxy-3-isopropylamino)propoxy&rsqb;phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture, are disclosed.

Esmolol formulation

A ready-to-use injectable, aqueous pharmaceutical composition for the treatment of cardiac conditions, comprising methyl-3-&lsqb;4-(2-hydroxy-3-isopropylamino) propoxy&rsqb; phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, as well as a method for its manufacture in a container, is disclosed.

Growing community of inventors

North Plainfield, NJ, United States of America

George Owoo